Smit AJT, Van der Maas NG, Van der Holt B, Van Norden Y, Van Werkhoven E, Vangsted AJ, Ypma PF, Visser-Wisselaar HA, Troia R, Boccadoro M, Löwenberg B, Janssen JJWM, Ossenkoppele GJ, Schjesvold F, Sonneveld P, Zweegman S, Versluis J, Cornelissen JJ(2025) The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology Haematologica(in press) DOI 10.3324/haematol.2025.288675, PubMed 41035401
Moore KLF, Rognvaldsson S, Szabo AG, Vaitekėnaitė V, Loigom D, Genell A, Thorsen J, Norgaard JN, Thorsteinsdottir S, Knut-Bojanowska D, Lysen A, Schjesvold F, Peceliunas V, Kaare A, Palk K, Parnat M, Sigurdsson A, Vangsted AJ, Blimark CH(2025) Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study Group Haematologica(in press) DOI 10.3324/haematol.2025.287344, PubMed 40905090
Ailawadhi S, Špička I, Spencer A, Lu J, Oriol A, Ling S, Schjesvold F, Berkovits A, Hus M, Li C, Dimopoulos MA, Rajnics P, Beşışık SK, Hungria V, Custidiano MDR, Parmar G, Leleu X, Li F, Cerchione C, Gomez C, Ishida T, Mateos MV, Buck TT, LeBlanc R, Minařík Jet al.(2025) Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study J Clin Oncol, 43(27), 3056 DOI 10.1200/JCO-25-01767, PubMed 40779730
